AVEO PHARMACEUTICALS, INC. AVEO Cash Flow

Aveo pharmaceuticals, inc. (AVEO)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities
Net income (loss)
452	9,388	35,667	-2,925	4,214	-5,329	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-28,017	-	-27,871	-14,987	-11,837	-15,001	-22,306	-44,660	-57,163	-52,739	-55,570	-65,440	-79,394	-107,029	-111,784	-117,600	-115,233	-114,394	-118,083	-111,779	-87,964	30,648	0	0	0
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Impairment of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	232	232	232	5,330	7,600	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	30	13	110	5,084	9,567	13,016	13,993	9,869	6,219	3,700	3,594	3,713	3,775	3,597	3,235	2,864	2,510	2,208	2,035	1,828	1,654	0	0	0
Accretion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss (gain) on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-253	0	0	0	-	-	-	-	-83	0	0	0	-	-	-	-	-	-	-	-
Stock-based compensation
2,317	2,358	2,512	2,510	2,547	2,546	2,203	1,810	1,465	1,089	944	858	816	999	781	918	1,095	1,132	1,410	2,280	2,517	2,808	3,356	3,328	2,070	3,940	5,059	5,923	8,393	8,007	7,733	7,372	6,923	5,903	0	0	0
Non-cash interest expense
510	567	602	614	611	556	522	499	491	514	525	537	513	465	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash change in fair value of PIPE Warrant liability
-5,410	-11,577	-35,502	-21,284	-30,199	-19,919	-7,695	-329	34,721	33,740	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash charge for settlement costs (Note 13)
-	-	-	-	-	-667	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	432	543	654	788	0	0	0
Amortization of premium and discount on investments
0	-	-	-	-	-3	-35	-58	-76	-68	-44	-13	-8	-14	-7	-14	-23	-34	-36	-57	-115	-221	-389	-564	-822	-1,041	-1,154	-1,690	-2,000	-2,446	-3,162	-3,598	-3,918	-3,801	0	0	0
Changes in operating assets and liabilities:
Restricted Cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,997	0	0	0	-	-	-	-	-5	0	0	0	-	-	-	-	144	0	0	0
Accounts receivable
208	-1,395	746	-362	1,971	2,624	-2,031	528	-76	-625	1,385	-857	-1,060	-3,614	-1,344	-1,018	789	2,300	676	1,085	-307	1,357	-7,235	-6,662	-7,927	-19,665	-405	-1,285	-308	13,439	-449	-19,588	1,442	6,819	0	0	0
Tenant improvement allowance receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,833	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
424	742	330	-118	-766	-774	-1,058	-631	-805	-684	-459	147	704	340	839	-7	-39	116	-1,893	-2,231	-889	-1,503	-719	-1,759	-4,147	-3,179	0	0	0	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Other noncurrent assets
0	-	-	-	-	-15	-179	-345	-674	-955	-888	-58	561	827	907	222	-89	-96	119	91	-44	-50	-257	-232	-109	-31	-5	-26	269	200	78	126	-320	-335	0	0	0
Accounts payable
856	-2,033	-800	-859	-1,271	1,063	1,042	-539	103	250	761	1,279	2,936	760	892	514	-2,279	-1,820	-1,366	-1,933	-1	-993	-4,484	-3,730	-5,463	-6,390	-4,122	2,954	528	1,724	581	-8,662	-4,269	-343	0	0	0
Accrued contract research
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other accrued liabilities
-444	-362	-1,385	-129	-42	240	1,569	324	694	927	96	-85	-269	-609	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current liabilities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Settlement liability (Note 13)
-	-	-	-	-	-	-	-	-	-	-	-	-	-4,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-1,973	-934	263	422	579	1,052	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-4,807	1,562	-5,639	-7,838	-6,109	-7,353	2,793	5,254	5,061	10,982	-22,190	4,168	0	0	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-1,413	-	993	2,711	2,800	2,927	957	-640	-2,408	-17,623	-18,330	-17,782	-16,260	-1,293	-1,293	-1,293	-1,294	-1,293	-1,294	-2,230	-5,415	-12,224	0	0	0
Deferred research and development reimbursements
-126	-361	-295	-445	-513	-669	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-current liabilities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease exit obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,206	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,569	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-78	-37	115	178	78	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,863	1,337	-99	-138	0	0	0
Net cash used in operating activities
-6,150	-2,919	-2,165	-23,891	-26,964	-25,026	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-102,265	-77,339	-97,033	26,451	0	0	0
Investing activities
Purchases of property and equipment
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,942	13,532	13,526	10,660	3,668	8,776	9,579	9,603	9,948	4,979	3,731	3,416	2,628	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-26,155	-	-23,602	-5,889	-12,729	-18,230	-29,266	-46,278	-50,252	-54,248	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of marketable securities
0	-	-	-	-	6,733	0	0	0	-	-	-	-	29,421	36,175	30,226	18,783	19,085	15,831	13,058	15,300	42,306	59,222	67,385	159,494	175,391	238,813	263,227	209,461	194,584	177,062	252,940	337,060	376,270	0	0	0
Proceeds from maturities and sales of marketable securities
0	-	-	-	-	25,312	34,812	41,510	30,735	24,450	25,878	23,666	29,416	28,664	20,236	16,025	17,550	11,550	16,710	34,575	52,639	109,767	135,355	167,630	222,406	191,129	233,299	269,254	273,443	339,779	349,063	334,950	292,930	234,795	0	0	0
Net cash provided by investing activities
0	-	-	-	-	18,579	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	167,022	78,279	-47,546	-144,103	0	0	0
Financing activities
Proceeds from issuance of common stock and warrants, net of issuance costs
-	25,279	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net of issuance costs
-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	53,637	0	0	0	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock to related parties
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of stock for stock-based compensation arrangements
-	-	-	-	-	494	0	0	0	-	-	-	-	36	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of principal of loan payable (Note 6)
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,241	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	5,734	-	-15,954	-14,203	-942	-6,316	2,047	21,820	33,270	54,710	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options and issuance of common and restricted stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payments of debt issuance costs
-	-	-	-	-	-	0	0	0	-	-	-	-	115	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	0	0	0
Principal payments on loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,612	8,517	7,026	8,018	7,785	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	35,776	-	17,187	18,657	-2,808	-1,126	1,978	7,862	5,182	1,018	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from refinancing of loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Principal payments on loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Net cash (used in) provided by financing activities
16,293	26,194	39,411	46,034	23,444	15,925	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	3,457	3,833	116,572	115,367	0	0	0
Net decrease in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	0	-17,251	-	3,984	5,529	15,355	-11,538	-22,369	-1,435	-16,479	-25,672	-25,241	-16,596	-11,800	1,480	9,560	9,540	-39,563	-25,334	-63,707	-51,964	12,829	32,654	68,214	4,773	-28,007	-2,285	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26	24	-3	4	-26	0	0	0	-	-	-	-
Supplemental cash flow information
Cash paid for interest
1,832	1,971	2,039	2,023	1,984	1,986	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use asset obtained in exchange for operating lease liabilities
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	1,684	-	1,452	1,452	1,667	1,983	2,190	2,140	2,082	2,018	2,080	2,386	2,681	2,916	3,081	3,173	3,161	3,104	3,058	3,013	3,003	3,016	0	0	0
Non-cash operating activity
Non-cash adjustment
Increase to deferred revenue due to adoption of ASC 606 - transition adjustment on January 1, 2018
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-cash activity
Deferred offering costs accrued at period end
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0